Page last updated: 2024-11-06

lysergic acid diethylamide and Neoplasms

lysergic acid diethylamide has been researched along with Neoplasms in 23 studies

Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases."9.19Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. ( Brenneisen, R; Doblin, R; Gasser, P; Holstein, D; Michel, Y; Passie, T; Yazar-Klosinski, B, 2014)
"We aim to provide an evidence-based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin."5.41Are psychedelics the answer to chronic pain: A review of current literature. ( Kooijman, NI; Kramers, C; Mulleners, WM; Reuser, A; van der Wal, SEI; Vissers, KCP; Willegers, T, 2023)
"A double-blind, randomized, active placebo-controlled pilot study was conducted to examine safety and efficacy of lysergic acid diethylamide (LSD)-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases."5.19Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. ( Brenneisen, R; Doblin, R; Gasser, P; Holstein, D; Michel, Y; Passie, T; Yazar-Klosinski, B, 2014)
"psilocybin, LSD) in treating cancer-related psychiatric distress."2.58Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. ( Ross, S, 2018)

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-199014 (60.87)18.7374
1990's1 (4.35)18.2507
2000's1 (4.35)29.6817
2010's4 (17.39)24.3611
2020's3 (13.04)2.80

Authors

AuthorsStudies
Barnett, BS1
Ziegler, K1
Doblin, R2
Carlo, AD1
Kooijman, NI1
Willegers, T1
Reuser, A1
Mulleners, WM1
Kramers, C1
Vissers, KCP1
van der Wal, SEI1
Simonsson, O1
Sexton, JD1
Hendricks, PS1
Ross, S1
Gasser, P2
Holstein, D1
Michel, Y1
Yazar-Klosinski, B1
Passie, T2
Brenneisen, R1
Kirchner, K1
Spiegel, D1
Stix, G1
SJOERDSMA, A1
KORNETSKY, C1
EVARTS, EV1
SCOTT, KG2
DANIELS, AE1
DAY, M1
STOCKBRIDGE, A1
STONE, RS1
Li, JH1
Lin, LF1
Phifer, B1
Grof, S1
Goodman, LE2
Richards, WA2
Kurland, AA2
Kast, E2
Jackson, LG1
Bishun, NP1
Raven, RW1
Williams, DC1
Monti, M1
Louria, DB1
Smith, JK1
Finkel, GC1
Pahnke, WN1
Jarvik, LF1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life[NCT05403086]Phase 2100 participants (Anticipated)Interventional2024-01-14Not yet recruiting
LSD-assisted Psychotherapy in Persons Suffering From Anxiety Associated With Advanced-stage Life Threatening Diseases. A Phase-II, Double-blind, Placebo-controlled Dose-response Pilot Study[NCT00920387]Phase 212 participants (Actual)Interventional2008-02-29Completed
EMPOWER Study: Exploring Medically Perceived Benefits, Use and Interest in Psychedelics and Cannabinoids: Observational Study With First Responders and Military Personnel Examining Previous Use Experience and Interest in Participating in Future Research S[NCT04965740]102 participants (Actual)Observational2021-06-04Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Baseline State-Trait Anxiety Inventory (STAI)

"The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Participants respond to each item by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so). STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety." (NCT00920387)
Timeframe: Baseline (Visit 4)

,
Interventionscore on a scale (Mean)
STAI-stateSTAI-trait
Active Placebo LSD (20 mcg)47.743.3
Full Dose LSD (200 mcg)53.153.2

Primary Endpoint State-Trait Anxiety Inventory (STAI)

"The STAI differentiates between State Anxiety, defined as anxiety experienced in reaction to a specific environmental circumstance, and Trait Anxiety, defined as long-standing nervous affect or anxiety disorder. The STAI-state subscale is a 20-item self-reported scale which assesses subjects' levels of transient, situationally oriented, anxiety. Participants respond to each item by selecting a response from a 4-point Likert scale ranging from 4 (Not at all) to 1 (Very much so). STAI-state scores are summed for a total score that range from 20 to 80, with higher scores indicating greater state anxiety. The STAI-trait subscale also consists of 20-items and is scored the same way, with total scores ranging from 20 to 80, with higher scores indicating greater trait anxiety." (NCT00920387)
Timeframe: 2 months after second experimental session

,
Interventionscore on a scale (Mean)
STAI-stateSTAI-trait
Active Placebo LSD (20 mcg)51.749.0
Full Dose LSD (200 mcg)41.545.2

Reviews

5 reviews available for lysergic acid diethylamide and Neoplasms

ArticleYear
Are psychedelics the answer to chronic pain: A review of current literature.
    Pain practice : the official journal of World Institute of Pain, 2023, Volume: 23, Issue:4

    Topics: Chronic Pain; Cluster Headache; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psiloc

2023
Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
    International review of psychiatry (Abingdon, England), 2018, Volume: 30, Issue:4

    Topics: Anxiety; Depression; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin; Serot

2018
Genetic toxicology of abused drugs: a brief review.
    Mutagenesis, 1998, Volume: 13, Issue:6

    Topics: Animals; Areca; Cannabis; Carcinogens; Chromosome Aberrations; Cocaine; Humans; Illicit Drugs; Lyser

1998
Chromosomes and cancer.
    Journal of surgical oncology, 1974, Volume: 6, Issue:2

    Topics: Carcinogens; Cell Transformation, Neoplastic; Cells, Cultured; Chromosome Aberrations; Chromosome Di

1974
[Teratogenic effects of LSD].
    Rivista di ostetricia e ginecologia, 1968, Volume: 23, Issue:5

    Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Aged; Animals; Child; Chromosome Aberrations; Female

1968

Trials

3 trials available for lysergic acid diethylamide and Neoplasms

ArticleYear
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
    The Journal of nervous and mental disease, 2014, Volume: 202, Issue:7

    Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up

2014
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
    The Journal of nervous and mental disease, 2014, Volume: 202, Issue:7

    Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up

2014
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
    The Journal of nervous and mental disease, 2014, Volume: 202, Issue:7

    Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up

2014
Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.
    The Journal of nervous and mental disease, 2014, Volume: 202, Issue:7

    Topics: Adult; Anxiety; Anxiety Disorders; Combined Modality Therapy; Cross-Over Studies; Female; Follow-Up

2014
LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects.
    Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:1

    Topics: Adult; Anxiety Disorders; Double-Blind Method; Emotions; Female; Follow-Up Studies; Humans; Lysergic

2015
LSD-assisted psychotherapy in patients with terminal cancer.
    International pharmacopsychiatry, 1973, Volume: 8, Issue:3

    Topics: Adult; Aged; Anxiety; Attitude to Death; Clinical Trials as Topic; Depression; Female; Humans; Lyser

1973

Other Studies

15 other studies available for lysergic acid diethylamide and Neoplasms

ArticleYear
Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data.
    Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:10

    Topics: Adult; Hallucinogens; Hematologic Neoplasms; Humans; Lysergic Acid Diethylamide; Neoplasms; Phenethy

2022
Associations between lifetime classic psychedelic use and markers of physical health.
    Journal of psychopharmacology (Oxford, England), 2021, Volume: 35, Issue:4

    Topics: Adult; Body Mass Index; Drug Users; Female; Hallucinogens; Health Status; Heart Diseases; Humans; Ly

2021
Psilocybin-assisted psychotherapy for dying cancer patients - aiding the final trip.
    Journal of psychopharmacology (Oxford, England), 2016, Volume: 30, Issue:12

    Topics: Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin; Psychotherapy

2016
Return of a problem child.
    Scientific American, 2009, Volume: 301, Issue:4

    Topics: Anxiety; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neoplasms; Psilocybin

2009
Lysergic acid diethylamide in patients with excess serotonin.
    A.M.A. archives of neurology and psychiatry, 1956, Volume: 75, Issue:5

    Topics: Carcinoid Tumor; Digestive System Neoplasms; Ergot Alkaloids; Gastrointestinal Tract; Lysergic Acid

1956
THE SIMILAR ACTION OF LYSERGIC ACID DERIVATIVES, HYPERTENSIN (CIBA) AND ALDOSTERONE UPON RB86 UPTAKE BY RED BLOOD CELLS FROM CONTROL AND CANCER SUBJECTS.
    Proceedings of the Western Pharmacology Society, 1963, Volume: 6

    Topics: Adenocarcinoma; Aldosterone; Angiotensin Amide; Angiotensins; Carcinoma, Squamous Cell; Erythrocytes

1963
THE EFFECTS OF DRUGS ON THE UPTAKE OF AMINES BY MAST CELLS.
    British journal of pharmacology and chemotherapy, 1964, Volume: 23

    Topics: Amines; Animals; Chlorpromazine; Cocaine; Ethanolamines; Guanethidine; Hallucinogens; Histamine; Imi

1964
The anti-tumor action of lysergic acid derivatives and their serotonin-blocking effect as reflected by the I 131 distribution in rats.
    Cancer research, 1959, Volume: 19

    Topics: Animals; Antineoplastic Agents; Iodine; Lysergic Acid; Lysergic Acid Diethylamide; Neoplasms; Radioi

1959
A review of the research and theological implications of the use of psychedelic drugs with terminal cancer patients.
    Journal of drug issues, 1977,Summer, Volume: 7, Issue:3

    Topics: Human Experimentation; Humans; Informed Consent; Lysergic Acid Diethylamide; Neoplasms; Psychotropic

1977
LSD and the dying patient.
    The Chicago Medical School quarterly, 1966,Summer, Volume: 26, Issue:2

    Topics: Chlorpromazine; Death; Humans; Lysergic Acid Diethylamide; Neoplasms; Palliative Care

1966
Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide.
    The Psychiatric quarterly, 1967, Volume: 41, Issue:4

    Topics: Affect; Analgesics; Attitude; Fear; Hallucinations; Humans; Lysergic Acid Diethylamide; Middle Aged;

1967
Chromosome aberrations--red herring or red flag?
    Journal of occupational medicine. : official publication of the Industrial Medical Association, 1973, Volume: 15, Issue:1

    Topics: Alkylating Agents; Anemia, Aplastic; Ataxia Telangiectasia; Benzene; Chromosome Aberrations; Down Sy

1973
Mycotoxins other than aflatoxins: tumor-producing potential and possible relation to human disease.
    Annals of the New York Academy of Sciences, 1970, Oct-30, Volume: 174, Issue:2

    Topics: Anemia, Aplastic; Animals; Edible Grain; Ergotism; Foodborne Diseases; Hallucinations; Humans; Leuke

1970
LSD-assisted psychotherapy with terminal cancer patients.
    Current psychiatric therapies, 1969, Volume: 9

    Topics: Adult; Female; Humans; Lysergic Acid Diethylamide; Male; Middle Aged; Neoplasms; Psychotherapy; Term

1969
Contradictions in LSD research.
    Science (New York, N.Y.), 1968, Nov-08, Volume: 162, Issue:3854

    Topics: Abnormalities, Drug-Induced; Chromosomes; Lysergic Acid Diethylamide; Neoplasms

1968